

5-31-2021

Do people with unilateral mid-portion Achilles tendinopathy who participate in running-related physical activity exhibit a meaningful conditioned pain modulation (CPM) effect: A pilot study

Myles C. Murphy

Ebonie K. Rio

Paola Chivers
Edith Cowan University

James Debenham

Sean I. Docking

See next page for additional authors

Follow this and additional works at: <https://ro.ecu.edu.au/ecuworkspost2013>



Part of the [Sports Sciences Commons](#)

[10.1016/j.jsams.2020.10.015](https://doi.org/10.1016/j.jsams.2020.10.015)

This is an author's accepted manuscript of: Murphy, M. C., Rio, E. K., Chivers, P., Debenham, J., Docking, S. I., Travers, M., & Gibson, W. (2021). Do people with unilateral mid-portion Achilles tendinopathy who participate in running-related physical activity exhibit a meaningful conditioned pain modulation (CPM) effect: A pilot study. *Journal of Science and Medicine in Sport*, 24(5), 441-447. <https://doi.org/10.1016/j.jsams.2020.10.015>

This Journal Article is posted at Research Online.
<https://ro.ecu.edu.au/ecuworkspost2013/10131>

Authors

Myles C. Murphy, Ebonie K. Rio, Paola Chivers, James Debenham, Sean I. Docking, Mervyn Travers, and William Gibson

© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

- 1 Do people with unilateral mid-portion Achilles tendinopathy who participate in running-related
- 2 physical activity exhibit a meaningful conditioned pain modulation (CPM) effect: A pilot study

3 **ABSTRACT**

4 **Objectives:** Our primary objective was to report the presence of a conditioned pain modulation
5 (CPM) effect in people with localised mid-portion Achilles tendinopathy and whether changes occur
6 over a 12-week period. Our secondary objectives were to quantify the proportion of participants who
7 present for tendinopathy research with previous interventions or co-morbidities, which may impact
8 the CPM-effect and investigate modulating factors.

9 **Design:** Prospective, observational cohort pilot study

10 **Method:** 215 participants presented for this Achilles tendinopathy research and were screened for
11 inclusion with nine being included. Included participants had the CPM-effect (cold-pressor test)
12 assessed using pressure pain thresholds at the Achilles tendon and quantified as absolute, relative and
13 meaningful change at baseline and 12-week follow-up.

14 **Results:** The most common reasons for exclusion were failure to meet a load-related diagnosis for
15 Achilles tendinopathy (15.5%), presence of confounding other injury (14.1%) and previous injection
16 therapy (13.6%). All participants had a meaningful CPM-effect at baseline and 12-week follow-up.
17 The mean (SD, n) baseline relative CPM effect (reduction in PPTs) was -40.5 (32.7, 9) percent.
18 Moderators of the CPM-effect as well as follow-up changes were not statistically analysed due to a
19 small sample size.

20 **Conclusion:** Based on these data, we would suggest that a homogenous population of patients with
21 chronic, unilateral mid-portion Achilles tendinopathy and no other co-morbidities are likely to exhibit
22 a meaningful CPM-effect. Impairments to endogenous analgesic mechanisms seen in people
23 presenting with mid-portion Achilles tendinopathy may be due to other confounding variables.

24

25 **KEY WORDS**

26 Tendon; descending inhibition; diffuse noxious inhibitory control; methodology

27

28 **PRACTICAL IMPLICATIONS**

- 29 • Methodological flaws in existing studies on conditioned pain modulation (CPM) of people
30 with Achilles tendinopathy have resulted in erroneous conclusions of the results.
- 31 • All participants with unilateral, mid-portion Achilles tendinopathy presenting with localised
32 tendon pain with a single leg hop had a meaningful CPM effect at baseline and 12-week
33 follow-up.
- 34 • Ninety-six percent of people presenting for inclusion to a mid-portion Achilles tendinopathy
35 CPM study were not appropriate for inclusion.
- 36 • This study suggests that impaired descending pain inhibition is unlikely to be a key driver in
37 the development of persistent mid-portion Achilles tendinopathy

38

39 INTRODUCTION

40 Pain science is an increasingly popular field within sports medicine and can help explain why
41 different pathologies and clinical presentations behave the way they do. The efficacy of endogenous
42 analgesia in response to a nociceptive stimulus is considered a key factor in understanding
43 musculoskeletal conditions. These endogenous responses may assist in patient-profiling and in turn
44 assist in directing treatment pathways.¹ This is especially relevant for chronic musculoskeletal pain
45 where many presentations demonstrate features of dysfunctional, or absent endogenous analgesic
46 mechanisms.²

47 ‘Conditioned Pain Modulation’ (CPM) is a reliable method to investigate endogenous analgesia.³ The
48 CPM paradigm involves assessing sensitivity, such as mechanical sensitivity via pressure pain
49 thresholds (PPTs) or thermal sensitivity, before and after the application of an ongoing, tonic painful
50 stimulus, such as ice water bath immersion.⁴ The assessment of sensitivity (e.g. PPTs) is referred to as
51 the test stimulus and the painful stimulus (e.g. ice water) is referred to as the conditioning stimulus. A
52 meaningful CPM response is to observe a reduction in mechanical sensitivity after application of the
53 conditioning stimulus. CPM is a well-established paradigm for investigating endogenous analgesia in
54 chronic pain states, such as chronic lower back pain.^{2 5} Current recommendations are that the size of
55 the CPM effect (which is the difference in the testing stimulus before and after application of the
56 conditioning stimulus) is reported as both absolute (raw scores) and relative (percentage change from
57 baseline) values⁴ and whether a meaningful CPM effect was elicited (CPM effect greater than the
58 standard error of the measurement). Such recommendations recognise that the baseline measure of
59 sensitivity (such as PPTs) likely differs between painful versus pain-free groups due to peripheral/ and
60 or central sensitisation.⁶ The use of relative change accounts for this difference.

61 The causes of tendon pain are not fully understood and little research regarding the role of central pain
62 mechanisms for tendinopathy exist, especially within the Achilles tendon.⁷ While widespread
63 mechanical sensitivity (but not temporal summation) has been shown to be a feature in Achilles
64 tendinopathy⁸ the CPM effect in people with mid-portion Achilles tendinopathy has been investigated
65 in just one study with a reduction in the *absolute* CPM effect being reported within the painful versus

66 pain-free group.⁹ This study compared the CPM effect in people with mid-portion Achilles
67 tendinopathy to a pain-free control group, finding a reduced CPM effect in the presence of persisting
68 Achilles tendon pain.⁹ This result should be interpreted with caution though as the analysis was based
69 on the *absolute* CPM effect. Given the large difference in baseline PPT between groups (Achilles
70 tendinopathy group baseline PPT 253kPa; Control group baseline PPT 671.4kPas ($p < 0.001$),⁹ the
71 *relative* CPM effect is the appropriate comparison. Importantly, when we calculated the relative CPM
72 effect there was no significant difference between groups (Appendix A).

73 Basic science research investigating pain phenomena such as endogenous analgesia relies on carefully
74 controlled testing paradigms where confounding factors are minimised.⁶ One common confounding
75 factor in musculoskeletal pain research is the presence of co-morbidities and these are common
76 exclusion criteria. In the case of CPM, comorbidities, such as lower back pain or knee osteoarthritis
77 can affect the CPM response.¹ As such, it can be strongly argued that they should be considered
78 exclusion criteria to avoid drawing erroneous conclusions regarding the condition of interest.⁶ Studies
79 examining Achilles tendinopathy commonly enrol athletic populations^{10 11} who likely have a high
80 incidence of confounding injuries yet the study by Tompra et al. did not report they excluded any
81 participants due to comorbidities such as concurrent pain sites (e.g. lower back pain).⁹ For example,
82 up to 65% of running injuries that occur within competition require medical attention¹² and between
83 34-47% of runners report a time loss injury at short-term follow-up.¹² To generate clean and usable
84 Achilles tendinopathy-related CPM data, it is likely that a number of potential participants would need
85 to be excluded due to comorbidities or participant comorbidities should be recorded and accounted for
86 within statistical analysis.⁶

87 In addition to concurrent injuries a plethora of other factors have been shown to influence the CPM
88 effect including age,² ethnicity¹³ and gender.² Physical activity levels have also been shown to
89 influence the CPM effect¹⁴ and specifically the magnitude of the CPM effect assessed at the Achilles
90 tendon has been shown to differ between runners and non-runners in healthy controls.¹⁵ Specific to the
91 assessment procedures for CPM the temperature of the conditioning stimulus as well as the induced
92 pain have been theorised to influence the reliability of the CPM effect.³ Due to the potential influence

93 of these factors on the CPM effect research reporting the CPM effect should either include a
94 homogenous sample or account for them within statistical analysis.⁶

95 There are no published studies, to the authors knowledge, on the stability of the CPM effect over time
96 in people with mid-portion Achilles tendinopathy. This is important to quantify as if the CPM effect is
97 not stable over time erroneous conclusions regarding the efficacy of interventions targeted towards
98 addressing impairments to descending inhibition (e.g. exercise rehabilitation or cognitive functional
99 therapy) may be attributed.

100

101 **OBJECTIVES**

102 Our primary objectives were to:

- 103 1. Report the absolute, relative and meaningful CPM effect in people with only localised
104 midportion Achilles tendon pain.
- 105 2. Report whether the CPM effect changes over the course of 12 weeks.

106 Our secondary objectives were to:

- 107 1. Quantify the proportion of participants that present for inclusion in Achilles tendinopathy
108 CPM research who are included/ excluded based on study inclusion/ exclusion criteria.
- 109 2. Investigate potential modulating factors for changes in the CPM effect over time (such as
110 level of pain and disability or fear of movement).

111

112 **METHODS**

113 A prospective, observational cohort pilot study was performed with two testing occasions based 12-
114 weeks apart (12-weeks being the most commonly used reassessment point within longitudinal, mid-
115 portion Achilles tendinopathy studies).¹⁰ Due to the outbreak of the Coronavirus COVID-19,
116 recruitment was ceased approximately 10 months prior to the planned final recruitment date.

117 The XXXX Human Research Ethics Committee (Reference number: XXXX) approved this study.
118 This study was registered with the Australian New Zealand Clinical Trial Registry (ANZCTR):
119 12617000675325.

120 All recruitment occurred in XXX with all appointments occurring in a quiet, distraction-free
121 environment within either a biomechanics laboratory at XXXX or a private consulting room of a
122 sports medicine practice, XXXX.

123 We included participants determined to have mid-portion Achilles tendinopathy who met our
124 inclusion and exclusion criteria (Appendix B). We chose to exclude those participants with insertional
125 Achilles tendinopathy as it is considered a separate condition¹⁶ as well as those participants with
126 bilateral symptoms as this could impact the CPM effect as deficits in the CPM effect have been
127 correlated to the number of painful regions.¹⁷ We also chose to exclude physically inactive people due
128 to the potential influence on the CPM effect.¹⁵ Participants self-reported their age (years), sex
129 (male/female), height (cm), weight (kg) and duration of symptoms (weeks). Valid and reliable
130 outcome measures to assess pain over a specified time, pain with loading, tendon pain related
131 disability, fear of movement, patient perception of improvement and the conditioned pain modulation
132 effect were selected based on recent reviews of appropriate outcome measures within Achilles
133 tendinopathy research and CPM.^{3 15 18 19}

134 Physical activity levels were recorded using an activity diary for the seven days prior to baseline
135 testing. Reports included the type of physical activity, as well as its duration (mins) and intensity
136 (modified CR-10 RPE scale) and is reported as Arbitrary Units (AU)= duration x intensity.

137 Participants were asked to rate their average pain over the past week when performing Achilles
138 tendon loading exercise on an 11-point numerical rating scale with 0 representing “no pain” and 10
139 representing the “worst pain imaginable.”

140 Pain mapping was used to ensure symptoms were localised to the tendon when performing a loading
141 task.²⁰ After completing a series of five single leg hops, participants were asked to draw the location
142 of their pain on a pain map of the posterior ankle using their finger on a tablet. Each location of pain
143 was then transformed into a round figure and then all figures were superimposed as a single figure
144 within Adobe Illustrator 20.0.3 (Adobe Creative Cloud, Adobe Inc, 2019) to construct a combined
145 pain map of all participants.

146 All treatments occurring within the past 12 weeks, other than those resulting in study exclusion, were
147 recorded for participants.

148 Participants were asked to rate their pain with 5 consecutive single leg hops on an 11-point numerical
149 rating scale (NRS) with 0 representing “no pain” and 10 representing the “worst pain imaginable.”
150 Participants were cued to hop on the spot as high as possible at a comfortable pace and to land on the
151 forefoot without the heel touching the floor to maximise the stretch-shorten load through the Achilles
152 tendon.

153 The Victorian Institute of Sport Assessment – Achilles (VISA-A) was used to assess participants
154 Achilles tendon specific disability.²¹ The VISA-A is a reliable and validated patient-reported outcome
155 measure for the assessment of pain and function with a maximum score of 100 representing no tendon
156 related disability.²¹

157 Fear of movement was assessed using the Tampa Scale of Kinesiophobia (TSK), a patient-reported
158 outcome measure commonly used in chronic lower back pain research²² that is now being used in
159 other musculoskeletal pain conditions . The TSK has a cut-off of greater than 37 points used to
160 represent maladaptive fear of movement.²³

161 Patient perception of improvement over the course of the study was measured via the 7-point Patient
162 Global Impression of Change (PGIC) scale, with options ranging from very much worse to very much
163 improved.²⁴ The PGIC was only used to assess perceived change at follow-up.

164 Pressure pain thresholds were used as the test stimulus and determined using a manual algometer with
165 a 1 cm diameter, circular tip (Force Ten™ FDX digital force gage, Wagner Instruments, Greenwich,
166 CT; annually calibrated). All assessments were performed by the same examiner (MM), an
167 experienced physiotherapist with over five years of experience and having received training in
168 assessment of the CPM effect using an identical procedure to that previously reported (Appendix C).¹⁵

169 The conditioning stimulus used was the cold pressor test and involved a bucket of ice water that was
170 placed next to the participant with the temperature maintained as close to five degrees Celsius as
171 possible (range 3-6 degrees). Participants immersed their hand to the level of the wrist, selected as
172 contralateral to the painful Achilles. Their hand remained immersed until instructed to remove by the
173 examiner (180 seconds) or the participant voluntarily removed the hand as a result of intolerance to
174 cold. However, no participants removed their hand prior to 180 seconds.

175 The test stimulus was assessed at the Achilles tendon at baseline, 60 seconds and 180 seconds after
176 hand immersion. Mean follow-up PPT was calculated from these values (60 seconds and 180 seconds)
177 and the CPM effect was calculated as the difference between the mean follow-up and baseline PPT
178 values. A negative value (e.g. -25) reflects an increase in the PPT after introduction of the conditioned
179 stimulus (i.e. a reduction in the mechanical sensitivity).¹⁵ The **absolute** CPM effect refers to the
180 difference in N/cm² from baseline and after introducing the conditioning stimulus whereas the
181 **relative** CPM effect refers to the percentage difference after introducing the conditioning stimulus.¹⁵

182 Reliability of the CPM testing procedure for this assessor has previously been reported as ICC
183 (3,1)(95% confidence interval- 95%CI) as 0.99 (0.95-1.00) and 0.96 (0.83-0.99) for parallel and
184 sequential paradigm testing of the Achilles tendon, respectively.¹⁵ This results in a relative CPM
185 effect standard error of the measurement of 2.21% and 3.97% for parallel and sequential paradigm
186 testing, respectively.¹⁵ If the relative CPM effect was greater than the SEM and reduced PPTs it is

187 referred to as **meaningful**, if the relative CPM effect was greater than the SEM but increased PPTs or
188 was not greater than the SEM it is referred to as absent.²⁵

189 Power calculations were performed in G.Power to determine the sample size needed for within group,
190 single arm pre/post parametric t-tests using the relative CPM effect calculated from the data provided
191 in Tompra et al.⁹ (appendix A) With $\alpha=0.05$ and $\beta=0.8$ it was determined a sample size of 25 would
192 be required.

193 All demographic data are presented as mean, median, standard deviation (SD) and range as
194 applicable. Data from outcome measures are presented as count, frequency, mean, SD, median and
195 range as applicable. The effect size (Cohens D) and 95%CI were calculated for all measures assessed
196 at baseline and follow-up (https://www.psychometrica.de/effect_size.html). The influence of potential
197 factors on the CPM effect (participant age, participant gender, duration of the condition, BMI,
198 physical activity levels, Achilles tendon related disability, fear of movement, pain with function/
199 loading, baseline pain over time, pain due to the conditioning stimulus) would be explored using
200 generalised estimated equations however these were not performed due to a small sample size. The
201 relationship between the change in the VISA-A and the relative CPM effect from baseline to follow-
202 up are presented graphically and tests of correlation were not performed due to low numbers.

203

204 RESULTS

205 Between 01/06/2017 and 01/03/2020, 215 participants presented for this Achilles tendinopathy
206 research and were screened for inclusion. Of all screened participants, 9 were identified as having no
207 confounders, with only localised mid-portion pain on the loading tests. The reasons for exclusion of
208 remaining participants are presented in Figure 1 with the detailed reasons presented in Appendix D.

209 Nine participants (4 female, 5 male) were included at baseline. All baseline demographic and outcome
210 measure data are presented within Table 1 as mean, SD, median and minimum to maximum. All
211 participants had a meaningful CPM effect. All participants had pain localised to the Achilles tendon
212 (during tendon loading) with the combined pain patterns depicted in Figure 2. Only 1 of the 9
213 participants reported having had any previous treatment (not resulting in exclusion) which was a
214 stretching program, which was not considered to have significant influence on our outcome measures.

215 Six participants (2 female, 4 male) completed both baseline and follow-up testing and were included
216 within analysis of within group change from baseline. The mean (SD) baseline, follow-up and within-
217 group differences for physical activity level, average pain with tendon loading over the past 7 days,
218 pain with tendon loading activity, tendinopathy related disability, fear of movement and the
219 conditioned pain modulation effect are presented within Table 2.

220 Two participants reported being “minimally worse” after 12 weeks, 3 participants reported being
221 “minimally improved” after 12 weeks and 1 participant reported being “very much improved” after 12
222 weeks.

223 While all participants reported being physically active at the time of injury not all were performing
224 physical activity at the time of baseline assessment. Over the course of the 12 weeks there appeared to
225 be an increase in physical activity levels due to a moderate effect size. However, due to the small
226 sample size this estimate is not very precise.

227 Participants appeared to report relatively low levels of pain with loading over the past 7 days at
228 baseline (mean NRS= 3.2/10), which reduced at follow-up (mean NRS= 1.2/10) representing a large
229 effect size. However, due to the small sample size this estimate is not very precise.

230 Participants appeared to report relatively low levels of pain with single leg hopping at baseline (mean
231 NRS= 1.8/10) which reduced at follow-up (mean NRS= 1.3/10) representing a small effect size.
232 However, due to the small sample size this estimate is not very precise.

233 A small improvement in the VISA-A score from baseline to follow-up (mean= 7.7 points) was seen
234 representing a small effect size.

235 Both baseline (mean=35 points) and follow-up (mean= 32 points) mean TSK scores were less than 37
236 points indicating no fear of movement. There was a small improvement in these scores over time
237 representing a moderate effect size.

238 The distribution of the PPTs for both baseline and follow up assessments can be seen within
239 Appendix E showing a decrease in sensitivity at both the 60 second and 180 second follow-up
240 following application of the conditioning stimulus. There was a large effect size for changes in PPTs
241 from baseline to follow-up suggesting a decrease in mechanical sensitivity of the Achilles tendon over
242 time. There were also moderate to large effect sizes for changes in the absolute and relative CPM
243 effect over time indicating a reduction in the size of the CPM effect. However, given the large
244 changes in the baseline PPTs this may be confounded by that change and cannot be accounted for
245 within analysis with our current sample size.

246 The relationship between change in the VISA-A score and the change in the relative CPM effect is
247 shown in Appendix F and does not appear to demonstrate any association.

248

249

250 **DISCUSSION**

251 The present study aimed to quantify the CPM effect in people with mid-portion Achilles
252 tendinopathy, determine if the CPM effect changed over time and to quantify the proportion of
253 potential participants who would be appropriate for inclusion in a CPM study. We sampled a running
254 population and given that between 34-47% of runners report a time loss injury at short-term follow-
255 up,¹² we hypothesised that that we would have to exclude multiple potential participants due to the
256 presence of a co-morbidity. We hypothesised that most of the included participants would
257 demonstrate a meaningful CPM response.

258 We found that 206 (96%) potential participants who were screened for eligibility were not appropriate
259 for inclusion within our study design. Specifically, 53.5% of participants were excluded as they had a
260 confounder to assessment of the CPM effect meaning that even if they were included they would not
261 have helped answer our research question. We observed that all included participants had a
262 meaningful CPM effect at baseline suggesting that people with chronic, unilateral mid-portion
263 Achilles tendinopathy and no other co-morbidities do not exhibit impaired endogenous analgesic
264 mechanisms.

265 All nine participants in this study had a meaningful CPM effect at baseline. While the number of
266 overall participants within this sample is low, this suggests it is unlikely that an absent CPM effect is
267 common in people with mid-portion Achilles tendinopathy (when localised, load-related tendon pain
268 is used as the diagnostic criteria).. This is the first study to report a meaningful CPM effect in a
269 sample of individuals with mid-portion AT; whilst Tompra et al. have investigated this phenomenon,
270 they did not report the proportion of participants who had a meaningful CPM effect ⁹

271 The participants who completed the 12-week follow-up (n=6) appear to have a large reduction in
272 mechanical sensitivity (Cohens d (95%CI) = 1.22 (-0.01 to 2.46)) and a large reduction in the relative
273 CPM effect (Cohens d (95%CI) = 1.10 (-0.11 to 2.32)). However, given the large confidence intervals
274 caution should be taken in interpreting these results. Additional caution in interpreting the changes in
275 the relative CPM effect are needed without being able to model to determine the influence of how the

276 changes in mechanical sensitivity might have influenced the relative CPM effect given mechanical
277 sensitivity is used to calculate the CPM effect.

278 This study excluded 96% of people presenting for inclusion. The most common reasons for exclusion
279 were; failure to meet diagnostic criteria for Achilles tendinopathy (15.5%), presence of confounding
280 other injury (14.1%), previous injection therapy (13.6%), previous conservative management (11.2%),
281 insertional Achilles tendinopathy (9.2%) and not being physically active (7.3%). Of interest, the
282 original Achilles tendinopathy CPM study had only excluded 33% of people presenting with only the
283 two the following reasons; not Achilles tendinopathy or symptoms of less than 3 months, and
284 included people with heterogenous pain locations.⁹ This sample had different inclusion and exclusion
285 criteria to our current study (for example our study excluded all regions of persistent pain, not just
286 lower limb complaints) and this may explain the differences in results (Achilles tendinopathy group
287 baseline mean (SD) relative CPM effect was -24% (12.7) whereas in our study the mean (SD) relative
288 CPM effect was -40.5% (32.7)).

289 We recognise that the inclusion and exclusion criteria presented within our study may not reflect all
290 people who have Achilles tendinopathy (for example we excluded participants with concurrent lower
291 back pain). However, for basic science research investigating centrally driven pain modulatory
292 mechanisms having a clean sample is vital to understanding the condition and making conclusions
293 from the data specific to the pain condition of interest.^{16 15} This study design allows us to make the
294 conclusion that it is the condition of interest, Achilles tendinopathy, and not other persistent pain
295 conditions participants may have which is associated with meaningful, or absent, CPM effects.

296 The most significant limitation of this study is the small sample size (n=9). Given that this study
297 recruited over more than a two-year period with more than 200 people screened for inclusion, our
298 small final sample was homogeneous, including participants with only chronic, unilateral mid-portion
299 Achilles tendinopathy and no other confounders. This strategy removed confounders that may impact
300 our objective of ascertaining whether chronic mid-portion Achilles tendinopathy results in an absent
301 CPM effect. Due to the small sample size we were also unable to perform any statistical analysis or
302 control for confounding variables (e.g. participant gender, physical activity levels)^{26 27} which would

303 be suggested in pain science research.^{6 15} This study also collected the testing stimulus over the
304 painful Achilles and not in the upper limb which could be viewed as a limitation. However, given the
305 conditioning stimulus was applied to the upper limb (e.g. distal to the Achilles tendon) it is feasible
306 that changes in the PPT are from central processing changes. It has also been previously shown that
307 the CPM effect is not consistent between testing sites which decreases the value of inferences based
308 on comparing different testing regions^{15 28 29} but future studies including multiple sites may strengthen
309 any inferences regarding central processing mechanisms.

310 Our recommendations to researchers designing a study investigating endogenous analgesic effects or
311 clinicians interpreting these results would be; 1) Strict screening procedures, ensuring participants
312 with confounding comorbidities are excluded, when undertaking CPM research. 2) analysis of the
313 CPM effect should account for potential confounders which are not excluded (e.g. participant gender,
314 physical activity levels), 3) reporting of the CPM effect should include absolute, relative and
315 meaningful change to avoid making erroneous conclusions about the presence or absence of
316 endogenous analgesic effects, and 4) diagnostic criteria for including participants should be clearly
317 stated to facilitate replication of research and translation.

318 **CONCLUSION**

319 This pilot study was able to demonstrate that of participants with unilateral, mid-portion Achilles
320 tendinopathy included, all had a meaningful CPM effect. Achilles tendinopathy was diagnosed using
321 criteria of localised, load-related tendon pain, and not palpation pain or imaging.³⁰ Our suggestion to
322 clinicians would be that based on this study and the revised analysis of Tompra et al.⁹ the previously
323 held assumption that mid-portion Achilles tendinopathy is associated with altered endogenous
324 analgesia cannot be supported within a sample of participants who did not have confounders to
325 assessment of the CPM effect. This pilot study demonstrated a large reduction in average pain over
326 the last seven days with Achilles tendon loading, Achilles tendon PPTs and the CPM effect over 12-
327 weeks, however caution is needed in interpreting these results due to the small sample size and wide
328 confidence intervals. This pilot study was also able to demonstrate that a large proportion of people
329 presenting for inclusion within mid-portion Achilles tendinopathy research are not appropriate for
330 inclusion if the studies outcome measures relate to basic pain science. Due to the large number of
331 participants presenting who had confounders to the CPM effect (such as chronic lower back pain or
332 patellofemoral pain) it may be that deficient endogenous analgesic mechanisms are present within a
333 clinical sample. However, based on this pilot study deficiencies in endogenous analgesia are unlikely
334 to be primary causative mechanisms to the development of Achilles tendinopathy symptoms.

335 **REFERENCES**

- 336 1. Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation
337 across different chronic pain conditions. *European Journal of Pain* 2018;22(2):216-41. doi:
338 10.1002/ejp.1140
- 339 2. Lewis GN, Rice DA, McNair PJ. Conditioned pain modulation in populations with chronic pain: a
340 systematic review and meta-analysis. *The journal of pain : official journal of the American*
341 *Pain Society* 2012;13(10):936-44. doi: 10.1016/j.jpain.2012.07.005 [published Online First:
342 2012/09/18]
- 343 3. Kennedy DL, Kemp HI, Ridout D, et al. Reliability of conditioned pain modulation: a systematic
344 review. *Pain* 2016;157(11):2410-19. doi: 10.1097/j.pain.0000000000000689
- 345 4. Yarnitsky D, Arendt-Nielsen L, Bouhassira D, et al. Recommendations on terminology and practice
346 of psychophysical DNIC testing. *European journal of pain (London, England)*
347 2010;14(4):339. doi: 10.1016/j.ejpain.2010.02.004 [published Online First: 2010/03/17]
- 348 5. Marcuzzi A, Wrigley PJ, Dean CM, et al. From acute to persistent low back pain: a longitudinal
349 investigation of somatosensory changes using quantitative sensory testing-an exploratory
350 study. *Pain reports* 2018;3(2):e641. doi: 10.1097/pr9.0000000000000641 [published Online
351 First: 2018/05/15]
- 352 6. Murphy M, Gibson W, Moseley GL, et al. Adopting a modern understanding of pain when
353 undertaking and critiquing research in sports medicine: an educational review. *British Journal*
354 *of Sports Medicine* 2020;Under review
- 355 7. Plinsinga ML, Brink MS, Vicenzino B, et al. Evidence of Nervous System Sensitization in
356 Commonly Presenting and Persistent Painful Tendinopathies: A Systematic Review. *The*
357 *Journal of orthopaedic and sports physical therapy* 2015;45(11):864-75. doi:
358 10.2519/jospt.2015.5895 [published Online First: 2015/09/22]
- 359 8. Eckenrode BJ, Kietrys DM, Stackhouse SK. PAIN SENSITIVITY IN CHRONIC ACHILLES
360 TENDINOPATHY. *International journal of sports physical therapy* 2019;14(6):945-56.
361 [published Online First: 2019/12/06]

- 362 9. Tompra N, van Dieen JH, Coppeters MW. Central pain processing is altered in people with
363 Achilles tendinopathy. *Br J Sports Med* 2016;50(16):1004-7. doi: 10.1136/bjsports-2015-
364 095476 [published Online First: 2015/12/25]
- 365 10. Murphy M, Travers MJ, Gibson W, et al. The rate of improvement of pain and function in mid-
366 portion Achilles tendinopathy with loading protocols: A Systematic Review and Longitudinal
367 Meta-Analysis. *Sports medicine (Auckland, NZ)* 2018;48(8):1875-91. doi: 10.1007/s40279-
368 018-0932-2.
- 369 11. Murphy MC, Travers MJ, Chivers P, et al. Efficacy of heavy eccentric calf training for treating
370 mid-portion Achilles tendinopathy: a systematic review and meta-analysis. *British Journal of*
371 *Sports Medicine* 2019;bjsports-2018-099934. doi: 10.1136/bjsports-2018-099934
- 372 12. Kluitenberg B, van Middelkoop M, Diercks R, et al. What are the Differences in Injury
373 Proportions Between Different Populations of Runners? A Systematic Review and Meta-
374 Analysis. *Sports medicine (Auckland, NZ)* 2015;45(8):1143-61. doi: 10.1007/s40279-015-
375 0331-x [published Online First: 2015/04/09]
- 376 13. Morris MC, Walker L, Bruehl S, et al. Race Effects on Conditioned Pain Modulation in Youth.
377 *The journal of pain : official journal of the American Pain Society* 2015;16(9):873-80. doi:
378 10.1016/j.jpain.2015.06.001 [published Online First: 2015/06/15]
- 379 14. Law LF, Sluka KA. How does physical activity modulate pain? *Pain* 2017;158(3):369-70. doi:
380 10.1097/j.pain.0000000000000792
- 381 15. Murphy M, Gibson W, Chivers P, et al. Considerations for multi-centre conditioned pain
382 modulation (CPM) research; an investigation of the inter-rater reliability, level of agreement
383 and confounders for the Achilles tendon and Triceps Surae *Br J Pain* 2020;In press
- 384 16. van Dijk CN, van Sterkenburg MN, Wiegelerinck JI, et al. Terminology for Achilles tendon related
385 disorders. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*
386 2011;19(5):835-41. doi: 10.1007/s00167-010-1374-z [published Online First: 2011/01/12]
- 387 17. Gruener H, Zeilig G, Laufer Y, et al. Differential pain modulation properties in central
388 neuropathic pain after spinal cord injury. *Pain* 2016;157(7):1415-24. doi:
389 10.1097/j.pain.0000000000000532 [published Online First: 2016/02/20]

- 390 18. Murphy M, Rio E, Debenham J, et al. Evaluating the progress of mid-portion Achilles
391 Tendinopathy during rehabilitation. A Review of Outcome Measures for Self- Reported Pain
392 and Function. *International journal of sports physical therapy* 2018;13(2):283-92. doi:
393 10.26603/ijspt20180283
- 394 19. Murphy M, Rio E, Debenham J, et al. Evaluating the progress of mid-portion Achilles
395 Tendinopathy during rehabilitation. A Review of Outcome Measures for muscle structure and
396 function, tendon structure and neural and pain associated mechanisms. . *International journal*
397 *of sports physical therapy* 2018;13(3):537-51.
- 398 20. Hannington M, Docking S, Cook J, et al. Self-reported jumpers' knee is common in elite
399 basketball athletes – But is it all patellar tendinopathy? *Physical Therapy in Sport*
400 2020;43:58-64. doi: <https://doi.org/10.1016/j.ptsp.2020.01.012>
- 401 21. Robinson JM, Cook JL, Purdam C, et al. The VISA-A questionnaire: a valid and reliable index of
402 the clinical severity of Achilles tendinopathy. *Br J Sports Med* 2001;35(5):335-41. [published
403 Online First: 2001/10/02]
- 404 22. Swinkels-Meewisse EJ, Swinkels RA, Verbeek AL, et al. Psychometric properties of the Tampa
405 Scale for kinesiophobia and the fear-avoidance beliefs questionnaire in acute low back pain.
406 *Manual therapy* 2003;8(1):29-36. [published Online First: 2003/02/15]
- 407 23. Corrigan P, Cortes DH, Pontiggia L, et al. THE DEGREE OF TENDINOSIS IS RELATED TO
408 SYMPTOM SEVERITY AND PHYSICAL ACTIVITY LEVELS IN PATIENTS WITH
409 MIDPORTION ACHILLES TENDINOPATHY. *International journal of sports physical*
410 *therapy* 2018;13(2):196-207.
- 411 24. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment
412 outcomes in chronic pain clinical trials: IMMPACT recommendations. *The journal of pain :*
413 *official journal of the American Pain Society* 2008;9(2):105-21. doi:
414 10.1016/j.jpain.2007.09.005 [published Online First: 2007/12/07]
- 415 25. Locke D, Gibson W, Moss P, et al. Analysis of meaningful conditioned pain modulation effect in
416 a pain-free adult population. *The journal of pain : official journal of the American Pain*

- 417 *Society* 2014;15(11):1190-8. doi: 10.1016/j.jpain.2014.09.001 [published Online First:
418 2014/09/23]
- 419 26. Martel MO, Wasan AD, Edwards RR. Sex differences in the stability of conditioned pain
420 modulation (CPM) among patients with chronic pain. *Pain medicine (Malden, Mass)*
421 2013;14(11):1757-68. doi: 10.1111/pme.12220 [published Online First: 2013/08/09]
- 422 27. Umeda M, Lee W, Marino CA, et al. Influence of moderate intensity physical activity levels and
423 gender on conditioned pain modulation. *Journal of sports sciences* 2016;34(5):467-76. doi:
424 10.1080/02640414.2015.1061199
- 425 28. Cathcart S, Winefield AH, Rolan P, et al. Reliability of temporal summation and diffuse noxious
426 inhibitory control. *Pain Res Manag* 2009;14(6):433-38. doi: 10.1155/2009/523098
- 427 29. Oono Y, Nie H, Matos RL, et al. The inter- and intra-individual variance in descending pain
428 modulation evoked by different conditioning stimuli in healthy men. *Scandinavian journal of*
429 *pain* 2011;2(4):162-69. doi: 10.1016/j.sjpain.2011.05.006 [published Online First:
430 2018/06/20]
- 431 30. Rio EK, Mc Auliffe S, Kuipers I, et al. ICON PART-T 2019–International Scientific
432 Tendinopathy Symposium Consensus: recommended standards for reporting participant
433 characteristics in tendinopathy research (PART-T). *British Journal of Sports Medicine*
434 2019;bjssports-2019-100957. doi: 10.1136/bjssports-2019-100957

435

436

437 **Table 1. Baseline variables (n= 9)**

	Mean	Standard deviation	Median	Minimum-maximum
Age (years)	42	9.3	41	30 to 54
Height (cm)	176.7	9.6	179	162 to 186
Weight (kg)	74.8	12.9	75	56 to 95
BMI (kg/m ²)	23.8	2.1	23.4	21.3 to 27.8
Duration of symptoms (weeks)	202.4	204.1	200	12 to 572
Physical activity level (AU)	228.3	378.8	90	0 to 1200
Average tendon pain with loading over past 7 days - NRS	3.3	2.2	3	1 to 7
VISA-A	59.7	13.4	63	44 to 80
TSK	36.8	5.4	37	24 to 43
Pain with single leg hop (NRS)	2.11	1.5	2	0 to 5
NRS- pain from conditioned stimulus	5.14	1.25	5	4 to 7.5
Achilles tendon PPT (n/cm ²)	58.8	23.3	55.5	30 to 106

CPM effect – absolute (n/cm ²)	-20.6	16.3	-14.8	-52.2 to -6
CPM effect – relative (%)	-40.5	32.7	-35.3	-100 to -6.8

438 BMI= Body mass index, AU= Arbitrary units, NRS= numerical rating scale, VISA-A= Victorian

439 institute of sport assessment – Achilles, TSK= Tampa scale of kinesiophobia, PPT= pressure pain

440 threshold, CPM= conditioned pain modulation

441 **Table 2. Within group differences from baseline to follow-up (n= 6)**

	Baseline mean (SD)	Follow-up mean (SD)	Mean difference (SD)	Cohens D (95% CI)
Physical activity level (AU)	290 (459.2)	585 (822.2)	295 (888.8)	0.44 (-0.70 to 1.59)
NRS- average tendon pain with loading over past 7 days	3.17 (1.9)	1.17 (1.6)	-2.0 (2.3)	-1.14 (-2.36 to -0.08)
VISA-A	58.8 (13.7)	66.5 (24.5)	7.7 (26.5)	0.388 (-0.75 to 1.52)
TSK	34.8 (5.5)	31.7 (7.3)	-3.2 (5.1)	-0.48 (-1.63 to 0.67)
NRS- pain with single leg hop	1.8 (1.2)	1.3 (1.8)	-0.5 (2.1)	-0.33 (-1.94 to 1.28)
NRS- pain from conditioned stimulus	4.5 (0.58)	5.0 (1.5)	0.41 (1.32)	0.44 (-0.71 to 1.59)
Achilles tendon PPT (n/cm ²)	56.5 (27.5)	91.9 (30.3)	35.4 (40.5)	1.22 (-0.01 to 2.46)
CPM effect – absolute	-18.6 (17.2)	-10.1 (10.3)	8.5 (26.1)	0.60 (-0.56 to 1.76)
CPM effect – relative	-39.3 (33.7)	-10.8 (14.3)	28.5 (43.9)	1.10 (-0.11 to 2.32)

442 Legend: SD= standard deviation, AU= arbitrary units, NRS= numerical rating scale, VISA-A=

443 Victorian institute of sport assessment- Achilles, TSK= Tampa scale of kinesiophobia, PPT= pressure

444 pain threshold, CPM= conditioned pain modulation.

446 **Figure 1. CONSORT Flow diagram**

447 **Figure 2. Combined pain maps**